Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

Phase 2

Conditions: Angioimmunoblastic T-cell Lymphoma

Interventions: Drug: Chidamide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2019-02-25

Last Posted Date: 2022-04-20

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 23

Registration Number: NCT03853044

Locations: 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Phase 2

Recruiting

Conditions: Cancer

Interventions: Drug: Durvalumab
Drug: Prednisone
Drug: Tremelimumab

First Posted Date: 2019-02-20

Last Posted Date: 2024-06-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 60

Registration Number: NCT03847649

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Windsor Regional Cancer Centre, Windsor, Ontario, Canada
🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada

and more 9 locations

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

Phase 3

Completed

Conditions: Prostatic Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Abiraterone acetate
Drug: Olaparib
Drug: Prednisone
Drug: Enzalutamide
Drug: Prednisolone

First Posted Date: 2019-02-08

Last Posted Date: 2024-02-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 793

Registration Number: NCT03834519

Locations: 🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 0081), Los Angeles, California, United States
🇨🇦
Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, Canada
🇺🇸
Beth Israel Deaconess Medical Ctr. ( Site 0093), Boston, Massachusetts, United States

and more 190 locations

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Phase 3

Completed

Conditions: Prostatic Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Docetaxel
Drug: Placebo
Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2019-02-08

Last Posted Date: 2024-07-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1030

Registration Number: NCT03834506

Locations: 🇨🇦
Lakeridge Health ( Site 0117), Oshawa, Ontario, Canada
🇨🇦
Sunnybrook Research Institute ( Site 0108), Toronto, Ontario, Canada
🇺🇸
Mount Sinai Hospital Medical Center ( Site 0042), Chicago, Illinois, United States

and more 212 locations

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer Metastatic
Prostate Cancer

Interventions: Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2019-02-07

Last Posted Date: 2024-12-04

Lead Sponsor: Martha Mims

Target Recruit Count: 130

Registration Number: NCT03833921

Locations: 🇺🇸
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States
🇺🇸
Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Ben Taub General Hospital, Houston, Texas, United States